Coexistence of BCR/ABL1 -positive chronic myeloid leukemia and JAK2 V617F -mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
Authors:
Open Access
- 31 March 2019
- journal article
- letter
- Published by Springer Nature in Blood Research
- Vol. 54 (1) , 77-79
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinibBlood Cancer Journal, 2015
- Imatinib and ruxolitinib association: first experience in two patientsHaematologica, 2014
- Concomitant occurrence of BCR-ABL and JAK2V617F mutationBlood, 2011
- CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemiaBlood, 2011
- JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disordersLeukemia, 2008
- JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemiaThe Lancet Oncology, 2007
- Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosisLeukemia, 2007
- Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutationBlood, 2007
- Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemiaLeukemia, 2007